I-Mab Stock Price, News & Analysis

I-Mab (Nasdaq: IMAB), a biopharmaceutical firm, will announce its financial results for the full year ending December 31, 2020, before the market opens on March 29, 2021. A conference call is scheduled for 8:00 a.m. ET on the same day, where the company will provide a corporate update. I-Mab aims to advance from a clinical stage to a fully integrated company with a robust pipeline of over 15 drug candidates in the immuno-oncology field. The call requires prior registration, and a replay will be available on the company’s website.

I-Mab (Nasdaq: IMAB) has announced the dosing of the first patient in the pivotal phase 3 trial for eftansomatropin alfa, targeting pediatric growth hormone deficiency in China. This long-acting recombinant human growth hormone is designed to improve patient compliance by allowing weekly injections, in contrast to daily alternatives. The trial will enroll 165 patients, comparing eftansomatropin alfa with Norditropin over 52 weeks. A successful trial could significantly improve the quality of life for children with growth hormone deficiency, addressing a substantial unmet need in China.

I-Mab (Nasdaq: IMAB) announced its participation in several upcoming virtual conferences in March 2021. Key conferences include the H.C. Wainwright Global Life Sciences Conference on March 9, the Credit Suisse Asian Investment Conference from March 22-26, and the Morgan Stanley Hong Kong Summit from March 29-31. Notable management participants include Dr. Jingwu Zang, Dr. Joan Huaqiong Shen, and CFO Jielun Zhu. The company is committed to advancing its pipeline of biologics in the immuno-oncology sector, aiming for rapid commercialization and global presence.

I-Mab (Nasdaq: IMAB) announced the clearance of its IND application by China's NMPA for TJ210/MOR210, allowing the initiation of a phase 1 clinical trial. This trial aims to evaluate the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors. TJ210/MOR210, a monoclonal antibody targeting C5aR1, is designed to block tumor-promoting immune cells. The trial follows similar studies in the U.S. and is expected to accelerate drug development for patients who have not responded to existing therapies.

I-Mab (Nasdaq: IMAB) announced a follow-on public offering of 3,283,950 American depositary shares, priced at US$54.00 each, by certain pre-IPO shareholders. The offering includes a 30-day option for underwriters to buy an additional 492,590 ADSs. Proceeds will not benefit the company as they are being sold by existing shareholders. The offering is made via a prospectus supplement filed with the SEC on February 5, 2021. The company focuses on developing novel biologics in the immuno-oncology field, with a pipeline of over 15 drug candidates.

I-Mab (Nasdaq: IMAB) announced a proposed registered underwritten public offering by certain pre-IPO shareholders of 3,283,950 American depositary shares (ADSs), each representing 23 ordinary shares. An additional option allows underwriters to purchase 492,590 more ADSs. The company will not receive proceeds from this sale. The offering is made under an automatic shelf registration statement filed with the SEC on February 5, 2021. BofA Securities, Piper Sandler, and Cantor Fitzgerald are joint bookrunners for the offering.

I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, has announced significant clinical advancements for its CD73 antibody, uliledlimab (TJD5), targeting advanced solid tumors. The company has initiated a phase 1/2 study in China and completed initial assessments in the U.S., demonstrating the safety and clinical activity of uliledlimab in combination with PD-1 inhibitors. Detailed results are expected at major conferences in 2021. I-Mab aims to offer innovative therapies for patients unresponsive to existing treatments.

I-Mab (NASDAQ: IMAB) announced the dosing of the first patient in a phase 2 clinical trial of TJ107 (efineptakin alpha), a long-acting recombinant human interleukin-7, for glioblastoma multiforme patients in China. The trial aims to evaluate the drug's efficacy in boosting lymphocyte counts post-chemoradiotherapy. Previous studies indicated TJ107's potential in improving immune function without severe toxicity. GBM remains a challenging cancer with poor outcomes, making innovative therapies like TJ107 critical for patients.

I-Mab (Nasdaq: IMAB) and MorphoSys (Nasdaq: MOR) have initiated a phase 1 dose escalation study for TJ210/MOR210 in the U.S., focusing on patients with relapsed or refractory advanced solid tumors. This monoclonal antibody targets the C5a receptor, aiming to disrupt tumor-promoting myeloid cells. Preclinical studies indicate safety and anti-tumor activity. The trial will inform the safety and tolerability of TJ210/MOR210, with future combination studies planned. MorphoSys will receive a $1.5 million milestone payment from I-Mab as part of their collaboration agreement.